Clinical Performance of a Multivariate Index Assay for Detecting Early-Stage Ovarian Cancer

Analysis of test performance revealed that Ova1 plus clinical assessment maintained a sensitivity of 95.3% which was superior to clinical assessment alone 68.6%, CA-125 62.8%, and modified ACOG guidelines 76.7%.